Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Shire Sees Future For Premature Baby Drug Despite PhII Disappointment

Executive Summary

Shire's product candidate for a rare eye disease in premature infants has failed in a Phase II study, but secondary endpoint data suggest SHP607 might still have a future.


Related Content

Shire buys Premacure for infant eye treatment